# PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Source: https://onco.cc/trials/nct06533384/  
OnCo record `nct06533384` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of capecitabine in triple-negative breast cancer, run by Guangdong Provincial People's Hospital, now recruiting.

## Summary

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC is a phase 3, randomised interventional study registered as NCT06533384 by Guangdong Provincial People's Hospital, with a registry enrolment figure of 310 participants, started 2024-08-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.; 9 cycles of Camrelizumab as adjuvant therapy.. Conditions listed: Triple-negative Breast Cancer. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06533384
- Phase: 3
- Setting: PARPi or Capecitabine Combined With PD-1 Inhibitors Was Selected Based on the Germline BRCA1/2 Mutation vs. PD-1 Inhibitors Alone as Adjuvant Therapy in High-risk Non-pCR TNBC
- Sponsor: Guangdong Provincial People's Hospital
- Enrolled: 310

## Sources

- ClinicalTrials.gov NCT06533384: https://clinicaltrials.gov/study/NCT06533384

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06533384.json